Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

NCT04589650 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA-related Overgrowth Spectrum (PROS)

Interventions

DRUG: Alpelisib
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals